Moderna's Flu Vaccine Receives Unanimous FDA Advisory Committee Endorsement
MRNA has more than doubled off its 52-week low of $22.28 on elevated volume (3.4× avg).
Summary
An FDA advisory committee voted unanimously in favor of the benefit-risk profile for Moderna's mRNA-1010 flu vaccine for adults aged 50 and older. This positive recommendation follows strong late-stage trial results and recent supportive indications from FDA staff reviewers. The vote significantly increases the probability of final FDA approval for the vaccine, which would mark a major expansion for Moderna beyond its COVID-19 portfolio. The final FDA decision is anticipated by the August 5 PDUFA date.
At the time of this announcement, MRNA was trading at $63.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $25.4B. The 52-week trading range was $22.28 to $67.74. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.